Evidence map›Paper›PMID 40805201›Full record

ArticleCancers2025

MicroRNA Expression Analysis and Biological Pathways in Chemoresistant Non-Small Cell Lung Cancer.

Chara Papadaki, Maria Mortoglou, Aristeidis E Boukouris, Krystallia Gourlia, Maria Markaki, Eleni Lagoudaki, Anastasios Koutsopoulos, Ioannis Tsamardinos, Dimitrios Mavroudis, Sofia Agelaki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chara PapadakiLaboratory of Translational Oncology, School of Medicine, University of Crete, 71500 Heraklion, Greece.ORCID 0000-0002-4591-3757
Maria MortoglouLaboratory of Translational Oncology, School of Medicine, University of Crete, 71500 Heraklion, Greece.
Aristeidis E BoukourisLaboratory of Translational Oncology, School of Medicine, University of Crete, 71500 Heraklion, Greece.ORCID 0000-0002-7106-0356
Krystallia GourliaLaboratory of Translational Oncology, School of Medicine, University of Crete, 71500 Heraklion, Greece.ORCID 0000-0002-4986-362X
Maria MarkakiDepartment of Computer Science, University of Crete, 71500 Heraklion, Greece.ORCID 0000-0001-5779-2078
Eleni LagoudakiDepartment of Pathology, University General Hospital of Heraklion, 71500 Heraklion, Greece.
Anastasios KoutsopoulosDepartment of Pathology, University General Hospital of Heraklion, 71500 Heraklion, Greece.ORCID 0000-0002-8430-7565
Ioannis TsamardinosDepartment of Computer Science, University of Crete, 71500 Heraklion, Greece.ORCID 0000-0002-2492-959X
Dimitrios MavroudisLaboratory of Translational Oncology, School of Medicine, University of Crete, 71500 Heraklion, Greece.
Sofia AgelakiLaboratory of Translational Oncology, School of Medicine, University of Crete, 71500 Heraklion, Greece.

Funding

This work is partly supported by the Anticancer Research Support Association (ARSA), the Hellenic Society of Medical Oncology (HeSMO) and Gnosis Data Analysis (Gnosis DA). n/a
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bioinformaticschemoresistancecisplatinmiRNAsnon-small cell lung cancer

Identifiers

PMID40805201
PMCPMC12346453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.